MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation
Werte in diesem Artikel
|
MindMaze Therapeutics Holding SA
/ Key word(s): Study results
Werbung
MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation GENEVA, SWITZERLAND and MECHANICSBURG, PA – March 31, 2026 – MindMaze Therapeutics and Vibra Healthcare today announced the results of a two-year multi-site quality improvement program demonstrating real-world evidence (RWE) that the integration of technology-enabled, high-dose therapy into standard inpatient rehabilitation significantly enhances functional recovery for stroke patients. These results were presented during the American Society of Neurorehabilitation (ASNR) annual conference. The initiative, implemented across five of Vibra’s inpatient medical rehabilitation facilities (IRFs), successfully delivered supplemental, gamified therapy to 210 patients. The program addressed a critical gap in stroke care: while clinical evidence supports higher doses of therapy for better recovery, staffing constraints and patient fatigue often limit delivery in the traditional standard of care (SOC). Werbung
Key Clinical Outcomes
Innovative Technology Platform Werbung
Exceptional Patient Experience "This initiative proves that high-dose, high-intensity technology-enabled therapy is both feasible and scalable across inpatient rehabilitation settings," said Brad Hollinger, Chairman and CEO of Vibra Healthcare. "By integrating MindMaze’s platform, we have increased therapy intensity without adding to the staffing burden, leading to meaningfully greater functional recovery for our patients." "The success of this partnership with Vibra Healthcare validates our mission to set a new global standard for neurorehabilitation," added Zach Henderson, CEO of MindMaze Therapeutics. "These RWE results show that the MindMaze Therapeutics platform is not just an add-on, but a vital component in maximizing patient outcomes and ensuring a seamless transition from hospital to home."
About MindMaze Therapeutics Media Contacts DISCLAIMER Additional features: File: Press release_MindMaze-Vibra_RWE Results at ASNR
End of Media Release |
| Language: | English |
| Company: | MindMaze Therapeutics Holding SA |
| Avenue de Secheron 15 | |
| 1202 Geneva | |
| Switzerland | |
| Phone: | +41 22 545 11 16 |
| Fax: | +41 22 545 11 17 |
| E-mail: | contact@relieftherapeutics.com |
| Internet: | www.mindmazetherapeutics.com |
| ISIN: | CH1251125998 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2300766 |
| End of News | EQS News Service |
|
|
2300766 31.03.2026 CET/CEST
Ausgewählte Hebelprodukte auf MindMaze Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf MindMaze Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle MindMaze Therapeutics Aktie News
MindMaze Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für MindMaze Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.